Recent studies on retatrutide, a dual stimulant for incretin hormone and gastric inhibitory polypeptide, suggest promising findings in treating weight gain and type 2 diabetes. Initial evidence from clinical assessments show substantial diminutions in body bulk and enhanced glucose regulation. Ongoing research is directed on long-term safety and us